Evidence map›Paper›PMID 41756679›Full record

ReviewHuman mutation2026

Apolonia Novillo, Marta Ysbert, Rocío Brea, Alicia María Hidalgo-Estévez, Fadoua El Abdellaoui-Soussi, Pablo Gómez-Del Arco

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Human mutation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Human mutation · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Apolonia NovilloDepartment of Cell Biology and Histology, Faculty of Medicine, Complutense University of Madrid, Madrid, Spain, ucm.es.ORCID https://orcid.org/0000-0003-0902-0991
Marta YsbertInstitute for Rare Diseases Research, Instituto de Salud Carlos III (ISCIII), Madrid, Spain, isciii.es.ORCID https://orcid.org/0009-0006-8598-0870
Rocío BreaInstitute for Rare Diseases Research, Instituto de Salud Carlos III (ISCIII), Madrid, Spain, isciii.es.ORCID https://orcid.org/0000-0003-0517-4045
Alicia María Hidalgo-EstévezDepartment of Basic Health Sciences, Universidad Rey Juan Carlos, Alcorcón, Spain, urjc.es.ORCID https://orcid.org/0000-0001-8849-7573
Fadoua El Abdellaoui-SoussiCenter for Stem Cells and Organoid Medicine (CuSTOM), Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA, cincinnatichildrens.org.ORCID https://orcid.org/0009-0004-7376-229X
Pablo Gómez-Del ArcoInstitute for Rare Diseases Research, Instituto de Salud Carlos III (ISCIII), Madrid, Spain, isciii.es.ORCID https://orcid.org/0000-0001-6748-7157

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chromodomain-helicase-DNA-binding protein 4 (CHD4) is a critical ATP-dependent chromatin remodeler that plays fundamental roles in transcriptional repression, DNA damage repair, and lineage specification, making it indispensable for cardiovascular development and function. Pathogenic

Indexed as

Cardiovascular DiseasesMi-2 Nucleosome Remodeling and Deacetylase ComplexMutationComputer SimulationGenetic Association StudiesGenetic Predisposition to DiseaseHumansPhenotypeProtein DomainsCHD4 protein, humanMi-2 Nucleosome Remodeling and Deacetylase Complexcardiovascular diseaseCHD4 mutationcongenital heart disease (CHD)Sifrim–Hitz–Weiss syndrome

Identifiers

PMID41756679
PMCPMC12935301

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.